The ITGA11+/ COL11A1+ CAFs subtype, therefore, may serve as a key determinant for the progression of NSCLC and may be considered for novel anti‐tumor strategies through the blockade of cancer cell–stroma interactions. The gene discussed is COL11A1; the disease is non-small cell lung carcinoma.